{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:06:00Z","timestamp":1791925560428,"version":"4.3.4"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Female urethral strictures (FUS) are rare, yet when present very bothersome. Repeated dilation often results in recurrence, requiring surgical urethral reconstruction in the long term. We assessed the outcomes of female patients with urethral stricture disease undergoing Optilume drug-coated-balloon (DCB) dilation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between August 2021 and May 2024, 14 female patients with FUS underwent DCB dilation. Two transgender male-to-female patients were excluded. The diagnosis was confirmed by inability to pass a 14Fr catheter, translabial ultrasound or voiding cystourethrogram (VCUG). Exclusion criteria were urinary tract infection, neurological disease and previous urethroplasty. Written consent was obtained prior to intervention and included the option of urethroplasty. After hydrophilic urethral dilation, urethrocystoscopy was performed. DCB (5\u00a0cm) dilation was done to 30Fr at 10\u00a0bar for 10\u00a0min. General or local anaesthesia was used depending on patient\u2019s preference. Transurethral catheter was placed for 2\u20135\u00a0days. Endpoints were urinary continence, anatomical success (\u2265\u200914Fr by cystoscopy\/calibration) and freedom from repeat intervention at 6\u00a0months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The mean age was 52.3\u00a0years (range: 31\u201381), the mean number of prior interventions was 4.3 (range: 0\u201340). The mean follow-up was 12\u00a0months (range: 6\u201341). At the time of analysis, 11 out of 12 subjects (91.7%) were free from recurrence and repeat intervention. All patients remained continent after the intervention, with two reporting complete resolution of preexisting incontinence. Limitations of the study include the small sample size, short follow-up and single centre nature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Optilume DCB dilation demonstrates short-term efficacy, is well tolerated, safe, and notably preserves sphincter function.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11255-025-04513-2","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T23:47:05Z","timestamp":1744847225000},"page":"3215-3217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Does Optilume drug-coated balloon dilation compromise female sphincter function?"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3606-2841","authenticated-orcid":false,"given":"Lukas Andrius","family":"Jelisejevas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennadi","family":"Tulchiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rehder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"4513_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/luts.12196","volume":"11","author":"S Malde","year":"2019","unstructured":"Malde S, Solomon E, Spilotros M et al (2019) Female bladder outlet obstruction: common symptoms masking an uncommon cause. Low Urin Tract Symptoms 11:72\u201377","journal-title":"Low Urin Tract Symptoms"},{"key":"4513_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11884-010-0071-6","volume":"5","author":"AL Ackerman","year":"2010","unstructured":"Ackerman AL, Blaivas J, Anger JT (2010) Female urethral reconstruction. Curr Bladder Dysfunct Rep 5:225\u2013232","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"4513_CR3","doi-asserted-by":"publisher","first-page":"102749","DOI":"10.1016\/j.fjurol.2024.102749","volume":"34","author":"B Peyronnet","year":"2024","unstructured":"Peyronnet B, Freton L, Marcelli F et al (2024) Female urethral stricture. Fr J Urol 34:102749","journal-title":"Fr J Urol"},{"key":"4513_CR4","doi-asserted-by":"publisher","DOI":"10.5812\/numonthly.15212","author":"F Heidari","year":"2014","unstructured":"Heidari F, Abbaszadeh S, Ghadian A et al (2014) On demand urethral dilatation versus intermittent urethral dilatation: results and complications in women with urethral stricture. Nephrourol Mon. https:\/\/doi.org\/10.5812\/numonthly.15212","journal-title":"Nephrourol Mon"},{"key":"4513_CR5","unstructured":"Dimitropoulos K, Greenwell T, Martins FE, et al. 2024 EAU Guidelines on urethral strictures. Edn. Presented at the EAU Annual Congress Paris 2024."},{"key":"4513_CR6","doi-asserted-by":"publisher","unstructured":"FDA approves the Optilume\u00ae urethral drug coated balloon for the treatment of urethral strictures. BJU Int. 2022 Mar; 129(3):305. https:\/\/doi.org\/10.1111\/bju.15716. PMID: 35297159.","DOI":"10.1111\/bju.15716"},{"key":"4513_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/bco2.312","volume":"5","author":"ME VanDyke","year":"2024","unstructured":"VanDyke ME, Morey AF, Coutinho K et al (2024) Optilume drug-coated balloon for anterior urethral stricture: 2-year results of the ROBUST III trial. BJUI Compass 5:366\u2013373","journal-title":"BJUI Compass"},{"key":"4513_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2021.101987","author":"J Stuehmeier","year":"2022","unstructured":"Stuehmeier J, Jelisejevas LA, Kink P et al (2022) Optilume\u00ae drug-coated balloon dilation in complex female urethral stricture. Urol Case Rep. https:\/\/doi.org\/10.1016\/j.eucr.2021.101987","journal-title":"Urol Case Rep"},{"key":"4513_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41416-019-0529-z","volume":"121","author":"CGCA Jackson","year":"2019","unstructured":"Jackson CGCA, Morris T, Hung N et al (2019) Breast milk paclitaxel excretion following intravenous chemotherapy\u2014a case report. Br J Cancer 121:421\u2013424","journal-title":"Br J Cancer"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04513-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04513-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04513-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:00:01Z","timestamp":1758808801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04513-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":9,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4513"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04513-2","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}